IBDEI042 ; ; 09-FEB-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4947,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Spleen
 ;;^UTILITY(U,$J,358.3,4947,1,4,0)
 ;;=4^C85.87
 ;;^UTILITY(U,$J,358.3,4947,2)
 ;;=^5001728
 ;;^UTILITY(U,$J,358.3,4948,0)
 ;;=C85.88^^22^216^419
 ;;^UTILITY(U,$J,358.3,4948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4948,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Mult Site Node
 ;;^UTILITY(U,$J,358.3,4948,1,4,0)
 ;;=4^C85.88
 ;;^UTILITY(U,$J,358.3,4948,2)
 ;;=^5001729
 ;;^UTILITY(U,$J,358.3,4949,0)
 ;;=C85.89^^22^216^413
 ;;^UTILITY(U,$J,358.3,4949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4949,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,4949,1,4,0)
 ;;=4^C85.89
 ;;^UTILITY(U,$J,358.3,4949,2)
 ;;=^5001730
 ;;^UTILITY(U,$J,358.3,4950,0)
 ;;=C85.90^^22^216^431
 ;;^UTILITY(U,$J,358.3,4950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4950,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,4950,1,4,0)
 ;;=4^C85.90
 ;;^UTILITY(U,$J,358.3,4950,2)
 ;;=^5001731
 ;;^UTILITY(U,$J,358.3,4951,0)
 ;;=C85.91^^22^216^424
 ;;^UTILITY(U,$J,358.3,4951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4951,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Head/Face/Neck Node
 ;;^UTILITY(U,$J,358.3,4951,1,4,0)
 ;;=4^C85.91
 ;;^UTILITY(U,$J,358.3,4951,2)
 ;;=^5001732
 ;;^UTILITY(U,$J,358.3,4952,0)
 ;;=C85.92^^22^216^428
 ;;^UTILITY(U,$J,358.3,4952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4952,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intrathoracic Node
 ;;^UTILITY(U,$J,358.3,4952,1,4,0)
 ;;=4^C85.92
 ;;^UTILITY(U,$J,358.3,4952,2)
 ;;=^5001733
 ;;^UTILITY(U,$J,358.3,4953,0)
 ;;=C85.93^^22^216^426
 ;;^UTILITY(U,$J,358.3,4953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4953,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intra-Abdominal Node
 ;;^UTILITY(U,$J,358.3,4953,1,4,0)
 ;;=4^C85.93
 ;;^UTILITY(U,$J,358.3,4953,2)
 ;;=^5001734
 ;;^UTILITY(U,$J,358.3,4954,0)
 ;;=C85.94^^22^216^422
 ;;^UTILITY(U,$J,358.3,4954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4954,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Axilla/Upper Limb Node
 ;;^UTILITY(U,$J,358.3,4954,1,4,0)
 ;;=4^C85.94
 ;;^UTILITY(U,$J,358.3,4954,2)
 ;;=^5001735
 ;;^UTILITY(U,$J,358.3,4955,0)
 ;;=C85.95^^22^216^425
 ;;^UTILITY(U,$J,358.3,4955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4955,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Ing Region/Lower Limb Node
 ;;^UTILITY(U,$J,358.3,4955,1,4,0)
 ;;=4^C85.95
 ;;^UTILITY(U,$J,358.3,4955,2)
 ;;=^5001736
 ;;^UTILITY(U,$J,358.3,4956,0)
 ;;=C85.96^^22^216^427
 ;;^UTILITY(U,$J,358.3,4956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4956,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,4956,1,4,0)
 ;;=4^C85.96
 ;;^UTILITY(U,$J,358.3,4956,2)
 ;;=^5001737
 ;;^UTILITY(U,$J,358.3,4957,0)
 ;;=C85.97^^22^216^430
 ;;^UTILITY(U,$J,358.3,4957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4957,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Spleen
 ;;^UTILITY(U,$J,358.3,4957,1,4,0)
 ;;=4^C85.97
 ;;^UTILITY(U,$J,358.3,4957,2)
 ;;=^5001738
 ;;^UTILITY(U,$J,358.3,4958,0)
 ;;=C85.98^^22^216^429
 ;;^UTILITY(U,$J,358.3,4958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4958,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,4958,1,4,0)
 ;;=4^C85.98
 ;;^UTILITY(U,$J,358.3,4958,2)
 ;;=^5001739
 ;;^UTILITY(U,$J,358.3,4959,0)
 ;;=C85.99^^22^216^423
 ;;^UTILITY(U,$J,358.3,4959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4959,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,4959,1,4,0)
 ;;=4^C85.99
 ;;^UTILITY(U,$J,358.3,4959,2)
 ;;=^5001740
 ;;^UTILITY(U,$J,358.3,4960,0)
 ;;=C86.0^^22^216^139
 ;;^UTILITY(U,$J,358.3,4960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4960,1,3,0)
 ;;=3^Extranodal NK/T-Cell Lymphoma,Nasal Type
 ;;^UTILITY(U,$J,358.3,4960,1,4,0)
 ;;=4^C86.0
 ;;^UTILITY(U,$J,358.3,4960,2)
 ;;=^5001741
 ;;^UTILITY(U,$J,358.3,4961,0)
 ;;=C86.2^^22^216^134
 ;;^UTILITY(U,$J,358.3,4961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4961,1,3,0)
 ;;=3^Enteropathy-Type T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,4961,1,4,0)
 ;;=4^C86.2
 ;;^UTILITY(U,$J,358.3,4961,2)
 ;;=^5001743
 ;;^UTILITY(U,$J,358.3,4962,0)
 ;;=C86.3^^22^216^476
 ;;^UTILITY(U,$J,358.3,4962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4962,1,3,0)
 ;;=3^Subcutaneous Panniculitis-Like T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,4962,1,4,0)
 ;;=4^C86.3
 ;;^UTILITY(U,$J,358.3,4962,2)
 ;;=^5001744
 ;;^UTILITY(U,$J,358.3,4963,0)
 ;;=C86.4^^22^216^68
 ;;^UTILITY(U,$J,358.3,4963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4963,1,3,0)
 ;;=3^Blastic NK-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,4963,1,4,0)
 ;;=4^C86.4
 ;;^UTILITY(U,$J,358.3,4963,2)
 ;;=^5001745
 ;;^UTILITY(U,$J,358.3,4964,0)
 ;;=C86.5^^22^216^57
 ;;^UTILITY(U,$J,358.3,4964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4964,1,3,0)
 ;;=3^Angioimmunoblastic T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,4964,1,4,0)
 ;;=4^C86.5
 ;;^UTILITY(U,$J,358.3,4964,2)
 ;;=^5001746
 ;;^UTILITY(U,$J,358.3,4965,0)
 ;;=C86.6^^22^216^445
 ;;^UTILITY(U,$J,358.3,4965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4965,1,3,0)
 ;;=3^Primary Cutaneous CD30-Positive T-Cell Proliferations
 ;;^UTILITY(U,$J,358.3,4965,1,4,0)
 ;;=4^C86.6
 ;;^UTILITY(U,$J,358.3,4965,2)
 ;;=^5001747
 ;;^UTILITY(U,$J,358.3,4966,0)
 ;;=C88.0^^22^216^478
 ;;^UTILITY(U,$J,358.3,4966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4966,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,4966,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,4966,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,4967,0)
 ;;=C88.2^^22^216^213
 ;;^UTILITY(U,$J,358.3,4967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4967,1,3,0)
 ;;=3^Heavy Chain Disease
 ;;^UTILITY(U,$J,358.3,4967,1,4,0)
 ;;=4^C88.2
 ;;^UTILITY(U,$J,358.3,4967,2)
 ;;=^55078
 ;;^UTILITY(U,$J,358.3,4968,0)
 ;;=C88.3^^22^216^235
 ;;^UTILITY(U,$J,358.3,4968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4968,1,3,0)
 ;;=3^Immunoproliferative Small Intestinal Disease
 ;;^UTILITY(U,$J,358.3,4968,1,4,0)
 ;;=4^C88.3
 ;;^UTILITY(U,$J,358.3,4968,2)
 ;;=^61964
 ;;^UTILITY(U,$J,358.3,4969,0)
 ;;=C88.4^^22^216^138
 ;;^UTILITY(U,$J,358.3,4969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4969,1,3,0)
 ;;=3^Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Assoc Lymphoid Tissue
 ;;^UTILITY(U,$J,358.3,4969,1,4,0)
 ;;=4^C88.4
 ;;^UTILITY(U,$J,358.3,4969,2)
 ;;=^5001749
 ;;^UTILITY(U,$J,358.3,4970,0)
 ;;=C88.8^^22^216^281
 ;;^UTILITY(U,$J,358.3,4970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4970,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases NEC
 ;;^UTILITY(U,$J,358.3,4970,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,4970,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,4971,0)
 ;;=C88.9^^22^216^282
 ;;^UTILITY(U,$J,358.3,4971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4971,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Unspec
 ;;^UTILITY(U,$J,358.3,4971,1,4,0)
 ;;=4^C88.9
 ;;^UTILITY(U,$J,358.3,4971,2)
 ;;=^5001751
 ;;^UTILITY(U,$J,358.3,4972,0)
 ;;=C90.00^^22^216^351
 ;;^UTILITY(U,$J,358.3,4972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4972,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,4972,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,4972,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,4973,0)
 ;;=C90.01^^22^216^350
 ;;^UTILITY(U,$J,358.3,4973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4973,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,4973,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,4973,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,4974,0)
 ;;=C90.02^^22^216^349
 ;;^UTILITY(U,$J,358.3,4974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4974,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,4974,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,4974,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,4975,0)
 ;;=C90.10^^22^216^444
 ;;^UTILITY(U,$J,358.3,4975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4975,1,3,0)
 ;;=3^Plasma Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,4975,1,4,0)
 ;;=4^C90.10
 ;;^UTILITY(U,$J,358.3,4975,2)
 ;;=^5001754
 ;;^UTILITY(U,$J,358.3,4976,0)
 ;;=C90.11^^22^216^443
 ;;^UTILITY(U,$J,358.3,4976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4976,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,4976,1,4,0)
 ;;=4^C90.11
 ;;^UTILITY(U,$J,358.3,4976,2)
 ;;=^267517
 ;;^UTILITY(U,$J,358.3,4977,0)
 ;;=C90.12^^22^216^442
 ;;^UTILITY(U,$J,358.3,4977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4977,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,4977,1,4,0)
 ;;=4^C90.12
 ;;^UTILITY(U,$J,358.3,4977,2)
 ;;=^5001755
 ;;^UTILITY(U,$J,358.3,4978,0)
 ;;=C90.20^^22^216^137
 ;;^UTILITY(U,$J,358.3,4978,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4978,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,4978,1,4,0)
 ;;=4^C90.20
 ;;^UTILITY(U,$J,358.3,4978,2)
 ;;=^5001756
 ;;^UTILITY(U,$J,358.3,4979,0)
 ;;=C90.21^^22^216^136
 ;;^UTILITY(U,$J,358.3,4979,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4979,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Remission
 ;;^UTILITY(U,$J,358.3,4979,1,4,0)
 ;;=4^C90.21
 ;;^UTILITY(U,$J,358.3,4979,2)
 ;;=^5001757
 ;;^UTILITY(U,$J,358.3,4980,0)
 ;;=C90.22^^22^216^135
 ;;^UTILITY(U,$J,358.3,4980,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4980,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Relapse
 ;;^UTILITY(U,$J,358.3,4980,1,4,0)
 ;;=4^C90.22
 ;;^UTILITY(U,$J,358.3,4980,2)
 ;;=^5001758
 ;;^UTILITY(U,$J,358.3,4981,0)
 ;;=C90.30^^22^216^475
 ;;^UTILITY(U,$J,358.3,4981,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4981,1,3,0)
 ;;=3^Solitary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,4981,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,4981,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,4982,0)
 ;;=C90.31^^22^216^474
 ;;^UTILITY(U,$J,358.3,4982,1,0)
 ;;=^358.31IA^4^2
